Friday June 1, 8:01 am Eastern Time
Press Release
SOURCE: ViroLogic, Inc.
ViroLogic Announces Conference Call to Review Research Presented at the 5th International Workshop on HIV Drug Resistance and Treatment Strategies
- Resistance Testing a Major Topic of Discussion -
SOUTH SAN FRANCISCO, Calif., June 1 /PRNewswire/ -- ViroLogic, Inc. (Nasdaq: VLGC - news) today announced that it will hold a conference call on Wednesday, June 6, 2001 at 4:00 p.m. (EDT) to review highlights of scientific studies presented at the 5th International Workshop on HIV Drug Resistance and Treatment Strategies in Scottsdale, Arizona.
Participating on the call from ViroLogic will be Bill Young, Chairman and Chief Executive Officer, Dr. Nicholas Hellmann, Vice President of Clinical Research, and Robin Toft, Vice President of Sales and Marketing. In addition, Dr. Susan Little, Assistant Adjunct Professor of Medicine in the Division of Infectious Diseases at The University of California San Diego will be available to review findings and answer questions about her study, ``Antiretroviral resistance and response to initial therapy among recently HIV infected subjects in North America.''
To take part in the call, please dial 888-674-1998 ten minutes prior to the start of the call and ask to be connected to the ViroLogic conference call. International callers may dial 212-993-0250. To access the call live via the web in listen-only mode, go to www.virologic.com.
Those unable to participate on the day of the call may listen to a replay available for 24 hours following the call by dialing 800-633-8284. International callers dial 858-812-6440. The reservation number needed to access the replay is 19028209. The replay will also be available for 30 days on ViroLogic's website.
About ViroLogic
ViroLogic is a biotechnology company advancing the fields of individualized medicine and pharmacogenomics, helping to make them realities in healthcare around the world today. The Company discovers, develops and markets innovative products to guide and improve treatment of serious viral diseases such as AIDS and hepatitis. Its industry-leading expertise in virology, molecular biology, clinical research, engineering, information systems, and quality assurance has resulted in technology to assess drug resistance and susceptibility in viruses that cause these diseases, which affect millions of people worldwide.
The Company's current products are designed to optimize HIV/AIDS treatment regimens, providing physicians with important information to help select appropriate drugs for their patients and leading to better outcomes and reduced costs. These products are also being used by nearly every major pharmaceutical company working to develop new and improved antiviral therapeutics that can be more effective in an increasingly drug-resistant environment.
SOURCE: ViroLogic, Inc. |
